Lund University welcomes Mikael Dolsten, head of research at Pfizer, as invited speaker to a webinar: 'Pfizer Rapid Response: Rising to Meet the Crisis' on February 12th at 15.45-17.15. Preregistration is required.
Mikael Dolsten, head of research at Pfizer, who led the development of Pfizer's and BioNTech's Covid-19 vaccine, was recently appointed as visiting professor at Lund University in Sweden.
Mikael Dolsten has been an advisor to the Obama administration and worked with the then vice-president and now the new president of the USA, Joe Biden, on the Cancer Moonshot initiative. He has been involved in R&D for some 30 drugs - most recently, he led the development of Pfizer's and BioNTech's Covid-19 vaccine as head of research at Pfizer.
His successful career began at Lund University, where he trained as a physician and later earned a PhD in tumour immunology. He spent 20 years in Lund and worked in the pharmaceutical industry at the Lund-based company Pharmacia, followed by Astra Draco. Now, with his visiting professorship at Lund University, he has come full circle.
The Faculty of Medicine welcomes all interested to participate in this webinar which will be given in English.
About the webinar:
Title: Pfizer Rapid Response: Rising to Meet the Crisis
February 12th at 15.45-17.15 (Swedish time)
Speaker: Mikael Dolsten, head of research at Pfizer
Other participants: Erik Renstrom, Vice-Chancellor at Lund University, Zackarias Soderlund (PhD student), Oscar Manouchehrian (PhD student), Sonja Aits, (Associate Senior Lecturer), Alex Evilevitch (Senior Lecturer, PI), Tomas Deierborg, Professor and moderator of the seminar
Registration:
Please note that you must register to participate in this seminar. Deadline February 10
Link to registration: https://webforms.med.lu.se/webinar-mikael-dolsten
Contact:
Ella Stensson
Events Project Leader
+46 722 08 87 92
ella.stensson@med.lu.se
(C) 2021 Electronic News Publishing, source ENP Newswire
PFIZER, INC. 
